← All trials
NCT05124561
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2021
- Primary completion
- Apr 15, 2022
- Completion date
- Aug 20, 2022
- First posted
- Nov 18, 2021
- Last posted
- Dec 2, 2021
- Enrollment
- 13000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tianjin Cansino Biotechnology IncLead sponsor
- Government of ChinaOverall official - principal investigator
- Beijing Institute of BiotechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.